What do systematic reviews say?

Clarithromycin vs placebo

• Medications for daytime sleepiness in individuals with idiopathic hypersomnia 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Rituximab vs placebo or control

Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.32 [0.14, 0.7]
  3 studies · 132 participants
  Moderate

Mycophenolate mofetil vs levamisole

Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.88 [0.41, 1.87]
  1 study · 149 participants
  Low

Mycophenolate mofetil vs levamisole

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mycophenolate mofetil vs levamisole

It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.32 [0.03, 3.01]
  1 study · 149 participants
  Very low

Mycophenolate mofetil vs levamisole

Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 1.26 [0.66, 2.4]
  1 study · 149 participants
  Low

Mycophenolate mofetil vs levamisole

It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.48 [0.04, 5.18]
  1 study · 149 participants
  Very low

Mycophenolate mofetil vs levamisole

It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 2.88 [0.12, 69.65]
  1 study · 149 participants
  Very low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 1.9 [0.66, 5.46]
  2 studies · 82 participants
  Low

Mycophenolate mofetil vs cyclosporin

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mycophenolate mofetil vs cyclosporin

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 3 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.3 [0.09, 1.07]
  3 studies · 144 participants
  Low

Rituximab vs placebo or control

Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.23 [0.12, 0.43]
  5 studies · 269 participants
  Moderate
• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.63 [0.42, 0.93]
  3 studies · 198 participants
  Moderate

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.23 [0.1, 0.5]
  3 studies · 140 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.08, 4.85]
  2 studies · 84 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.09 [0.02, 0.47]
  3 studies · 144 participants
  Low

Mycophenolate mofetil vs cyclosporin

Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.45]
  1 study · 24 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.52 [0.33, 0.82]
  8 studies · 474 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 0.65 [0.48, 0.88]
  8 studies · 462 participants
  Low

Levamisole vs steroids or placebo or both, or no treatment

The review found no eligible studies for this question.

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found